Page last updated: 2024-12-11
pirbenicillin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Description
pirbenicillin: RN given refers to (2S-(2 alpha,5 alpha,6 beta))-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 9871712 |
CHEMBL ID | 2110979 |
SCHEMBL ID | 305647 |
MeSH ID | M0059563 |
Synonyms (11)
Synonym |
---|
pirbenicillin |
8ary01xryu , |
55975-92-3 |
unii-8ary01xryu |
pirbenicillin [inn] |
SCHEMBL305647 |
CHEMBL2110979 |
DTXSID70204553 |
(2s,5r,6r)-6-[[(2r)-2-[[2-[[amino(pyridin-4-yl)methylidene]amino]acetyl]amino]-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
gtpl10845 |
Q27270119 |
Research Excerpts
Pharmacokinetics
Excerpt | Reference | Relevance |
---|---|---|
" The pharmacokinetic behavior of pirbenicillin and the other penicillins was analyzed by the two-compartment open model." | ( Pirbenicillin: pharmacokinetic parameters in mice. English, AR; Girard, D; Retsema, JA, 1976) | 0.26 |
Dosage Studied
Excerpt | Relevance | Reference |
---|---|---|
" A minor adjustment in dosage schedule is necessary in reduced renal function." | ( Pharmacokinetics of the new broad spectrum penicillin CP-33994-2. Bergan, T; Brodwall, EK; Orjavik, O, 1980) | 0.26 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (4)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 4 (100.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |